Stocktoria
Sol-Gel Technologies Ltd. SLGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-02-01
Chart by TradingView
5/9
Piotroski F — financial health
-19.59
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $19.4M | $11.5M | $1.6M | $3.9M | $31.3M |
| Operating income | -$7.5M | -$12.0M | -$29.3M | -$16.2M | $3.0M |
| Net income | -$6.1M | -$10.6M | -$27.2M | -$14.9M | $3.2M |
| Operating cash flow | $322,000 | -$13.9M | -$17.7M | -$9.5M | -$7.7M |
| Free cash flow | $275,000 | -$13.9M | -$17.9M | -$9.7M | -$7.8M |
| Total assets | $29.9M | $35.8M | $45.3M | $46.6M | $69.2M |
| Total liabilities | $7.1M | $7.0M | $6.6M | $4.4M | $13.6M |
| Shareholders' equity | $22.8M | $28.9M | $38.6M | $42.2M | $55.6M |
| Ratios | |||||
| Operating margin | -38.9% | -104.1% | -1885.8% | -418.3% | 9.5% |
| Net margin | -31.6% | -91.7% | -1752.8% | -384.3% | 10.3% |
| FCF margin | 1.4% | -120.4% | -1149.5% | -248.6% | -25.1% |
| Return on assets | -20.5% | -29.5% | -60.1% | -32.0% | 4.7% |
| Return on equity | -26.9% | -36.7% | -70.5% | -35.4% | 5.8% |
| Current ratio | 4.37 | 5.92 | 9.10 | 12.93 | 4.88 |
| Revenue growth | 68.0% | 642.5% | -60.0% | -87.6% | 260.6% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.59 (distress)
- Working capital / assets 0.695
- Retained earnings / assets -7.922
- EBIT / assets -0.252
- Equity / liabilities 3.21
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001684693 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.